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Abstract
Background: Over 14 million people die each year from infectious diseases despite extensive vaccine use [1]. The needle
and syringe—first invented in 1853—is still the primary delivery device, injecting liquid vaccine into muscle. Vaccines could
be far more effective if they were precisely delivered into the narrow layer just beneath the skin surface that contains a
much higher density of potent antigen-presenting cells (APCs) essential to generate a protective immune response. We
hypothesized that successful vaccination could be achieved this way with far lower antigen doses than required by the
needle and syringe.
Methodology/Principal Findings: To meet this objective, using a probability-based theoretical analysis for targeting skin
APCs, we designed the Nanopatch
TM, which contains an array of densely packed projections (21025/cm
2) invisible to the
human eye (110 mm in length, tapering to tips with a sharpness of ,1000 nm), that are dry-coated with vaccine and applied
to the skin for two minutes. Here we show that the Nanopatches deliver a seasonal influenza vaccine (FluvaxH 2008) to
directly contact thousands of APCs, in excellent agreement with theoretical prediction. By physically targeting vaccine
directly to these cells we induced protective levels of functional antibody responses in mice and also protection against an
influenza virus challenge that are comparable to the vaccine delivered intramuscularly with the needle and syringe—but
with less than 1/100
th of the delivered antigen.
Conclusions/Significance: Our results represent a marked improvement—an order of magnitude greater than reported by
others—for injected doses administered by other delivery methods, without reliance on an added adjuvant, and with only a
single vaccination. This study provides a proven mathematical/engineering delivery device template for extension into
human studies—and we speculate that successful translation of these findings into humans could uniquely assist with
problems of vaccine shortages and distribution—together with alleviating fear of the needle and the need for trained
practitioners to administer vaccine, e.g., during an influenza pandemic.
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Introduction
Vaccines can be more effective if they are delivered into the
narrow layer just beneath the skin surface that contains a high
density of antigen presenting cells (APCs) required to generate an
immune response [2–4], rather than into the muscle where suchcells
present at a much lower density (Fig 1). One key focus for
improvement is in achieving successful vaccination using the lowest
dose possible. This is particularly important in the context of a
rapidlyemergingdisease,suchaspandemicinfluenza,whereexisting
vaccination production methods are slow to meet the demand for
population protection [5]. Some success in tackling this problem has
been achieved by supplementing the vaccine with an adjuvant –
although in many cases with an increase of adverse reactions [6].
Alternatively, targeting of vaccines directly to large populations of
skin immune cells holds great potential in achieving protection, with
significant dose sparing and improved tolerability profiles.
So far, however, only limited dose sparing gains have been
achieved: delivery approaches vaccinating with conventional
antigens have yielded functional disease protection, but with dose
sparing gains of one order of magnitude compared to intramus-
cular injections without the use of an adjuvant. Most studies make
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10266use of a needle or microneedle(s) to deliver the vaccine to different
tissue sites; and we illustrate these schematically in Fig. 1 b–c.I ti s
compared to the current convention of most vaccines being
delivered with a needle into muscle (Fig 1a). The closest
alternative to this – and the most tested [7]– is delivering liquid
vaccine with a fine needle to the dermis (Fig 1b); with, for
example, influenza vaccines requiring one tenth of the antigen for
a comparable immune response as standard intramuscular
injection [3]. With a thinner target area, intradermal injection is
technically difficult to administer. Recently, this difficulty has been
mitigated by a more controlled fixed-penetration injection
mechanism [8] (.1mm in length) – with a finer needle
(,100 mm in diameter) – while still yielding similar immunological
results that are functional in the protection against disease (some
work was also presented with even greater dose-sparing than 1:10,
but this is limited to total antibody readouts – which do not yield
insights into protective efficacy against a particular disease).
However, needle-based intradermal vaccine approaches pierce
through the tightly-defined epidermal immune cell populations [2]
(abundant in a class of APCs called Langerhans cells), delivering
liquid vaccine as a single bolus into the dermis (Fig 1b) [2]. This
may not be the most effective way of targeting antigens to the skin
immune system: the epidermal immune cells are largely missed;
and further below, in the dermis, the ‘pooled’ vaccine reaches
dermal APCs, with much of it in the surrounding region away
from these cells – and not directly accessible to them. By increasing
the number of similarly shaped needles up to 5 – to deliver either
liquid or solid-coated vaccine (e.g. Fig 1c) – vaccine interaction
with the skin target cell populations is not fundamentally different;
and therefore the resultant immune responses are also similar to
individual needle injection to the dermis [4], [9], [10]. And by
further increasing the number of micro-needles in an array to 190
on a 1 cm
2 patch (then extended to 1314 microneedles on a 2 cm
2
patch) [11], [12], better immune responses have been achieved
following chicken egg albumin delivery (a non pathogenic protein;
functional protection against a disease has therefore not been
tested) in comparison with intramuscular injection. However, the
induced immune responses are no higher than achieved by needle
intradermal delivery. And dose-sparing effects were not explored
[11].
Recently, other methods of vaccine delivery moving completely
away from the needle (e.g., diffusion/permeation delivery [13],
liquid jet injection [14], and ballistic microparticle injection [15])
have been pursued to meet these delivery challenges. However,
their ability to consistently and directly deliver vaccines directly to
a high population of skin immune cells with minimal cell damage
is limited (resulting in comparable dose sparing gains as needle or
microneedle-based systems). Also, these devices are hindered by
practical considerations, such as size, expense of manufacture or
complexity of operation
Here, we present a new method of controlled and targeted
delivery of vaccine, to directly contact thousands of APCs residing
within the skin, without widespread cell death – and exploiting the
network of epidermal and dermal APCs [16] to significantly
improve vaccine potency over existing delivery approaches.
To achieve this goal, we designed a Nanopatch
TM device (shown
conceptually in Fig 1d; and Fig 2 a–c), displaying an array of
densely-packed (21025 projections/cm
2) gold-coated silicon projec-
tions (,110 mm in total length, including a cone of 40 mm height;
tapering to tip designs at ,1000 nm) coated with vaccine antigen in
dry form (Fig 1 d and 2 c). When applied to the skin, the concept is
for the Nanopatch
TM projections to penetrate the epidermis and
upper dermis, depositing antigen directly to high populations of
APCs residing within these skin layers (Fig 1 d). However, we also
design the slender projections at the micro-nanoscale (with much of
the length below the diameter of target cells), so that when they are
slowly applied to the skin (i.e. around 1 m/s, which is much lower
than the very high gene gun speeds), they induce low stresses to the
targetcells,and thusarelikelytoinducealowincidenceofcelldeath
nearthetips[17],[18].Indoingso,wearecombiningthebenefitsof
a more accurately directed delivery of vaccines to a high population
of APCs, without widespread cell death. As shown to scale in Fig 1,
Figure 1. The concept of targeting antigen directly to skin antigen presenting cells (APCs) (in the epidermis and dermis) using
Nanopatches
TM – compared to existing needle-based delivery methods. Drawn to scale is the structure of human skin (which is thicker than
mouse skin; including the location of Langerhans cells and dermal APCs). We also show, to scale, the geometry of different needle-based delivery
devices (a–c) and the Nanopatch
TM (d). (a) Intramuscular (IM) route directly inject a vaccine into muscle, which contains a low density of antigen
presenting cells. (b) Intradermal (ID) injection delivers vaccine to the dermis of the skin, where there is an extensive network of resident professional
APCs. These APCs can capture antigen, migrate to the draining lymph node, and orchestrate potent systemic immune responses. Therefore, ID
delivery can achieve comparable immune responses to IM, but at about one-tenth of the vaccine dose. However, it is technically challenging to do an
ID injection. (c) Microneedle techniques use sparsely packed needles with dimensions of hundreds of micrometers to deliver a liquid or dry form of
the vaccine to the skin. This method is technically easier and is as efficient as ID injection. (d) The Nanopatch
TM technique uses a very small and
densely packed array (over 20,000 projections/cm
2) to directly deposit vaccine material into the immediate vicinity of a large population of APCs in a
small area. Therefore, numerous APCs can be directly involved in raising an immune response.
doi:10.1371/journal.pone.0010266.g001
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having very high packing density of projections (.20000 projec-
tions/cm
2) tailored by a probability analysis to deposit antigen
directly tothousands ofepidermalanddermalAPCsmappedwithin
theskin,with the smallerdiameterfarlesslikelytodamage cellsnear
the projections.
In this study, we tested the ability of Nanopatches to deliver
seasonal influenza vaccine with delivered dose reduction. We
chose commercially-available seasonal human trivalent influenza
vaccine (FluvaxH 2008) as a test case, because an antigen-efficient
vaccine delivery system for influenza might overcome seasonal
vaccine shortages and allow a greater number of people to be
vaccinated quickly following the arrival of a pandemic strain [19],
[20]. In the event of a pandemic, the current influenza vaccine
production capacity of about 900 million doses [20] falls far short
of the global population; most of whom might need the vaccine.
Conceptually, however, we believe the Nanopatch is broadly
applicable to many other vaccines.
Figure 2. Nanopatch
TM appearance, application, and targeted delivery of antigen to antigen presenting cells (APCs). Nanopatches (a)
were fabricated (cone length 40 mm) with Deep Reactive Ion Etching and then visualized by scanning electron microscopy (SEM) uncoated (b) or dry
coated with FluvaxH2008 andmethylcellulose (c). The skin following Nanopatch
TM application was visualized using Cryo-SEM (d), the arrows show entry
points through the epidermis (SC: stratum corneum; E: viable epidermis; D: dermis). The localization of vaccine (red, panel e side view, panel i top
view; Cy3 labeled FluvaxH) and MHC class II +ve cells (green, f side view, panel j top view) was determined by confocal microscopy to the depth of
46 mm.Ahaircanbeseeninj andlasalargediagonalbar. Nuclear staining(blue,panelg andk;stainedwithHoechst33342) intheepidermis was used
to determine theepidermal-dermalboundary. Co-localizationis shownin panelh andl (arrowheads). Thedistaltip penetrationvaluesareshownin the
panel m. Quantification of MHC class II +ve cells, antigen and co-localized antigen and MHC class II +ve cells was carried out using data from 9 areas
within each of three treated ears (n,o,p ). An example of a confocal microscopy image in three dimensions is presented in Video S1.
doi:10.1371/journal.pone.0010266.g002
Skin Targeted Vaccinations
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A probabilistically guided approach for directly
depositing antigen to more than 50% of both epidermal
and dermal APCs, beneath the patch area
As our starting point we chose Langerhans cells, a key antigen-
presenting cell in the skin [16], as just one example target because
their depth and location are very well quantified [21]. First, we
determined the probability of a single projection contacting a
Langerhans cell:
Pcontact~Vtarget

Vlayer ð1Þ
Where:
Vlayer is the volume of the tissue layer containing the Langerhans
cells,
Vtarget the volume, including the target to which the vaccine can be
delivered.
In solving (1), we applied the knowledge of Langerhans density
and location: e.g. the mouse ear (C57BL/6 Strain) has 542617
Langerhans cells per square mm of skin [22], tightly distributed in
the vertical plane at a mean depth of 14.9 mm below the skin
surface for the mouse ear (in humans the density of these cells is
similar, but they are deeper), less than 3 mm above the dermo-
epidermal boundary and with a normal histogram distribution
[21]. We calculated that the chance of a tapering projection
contacting a Langerhans cell body was Pcontact=0.275. This
probability calculation is simplified and therefore conservatively
low: we assume that the contact event will be an antigen touching
the Langerhans cell body, and have not included the other contact
events with the network of dendrites extending from the
Langerhans cell. With each Langerhans cell possessing between
five and nine dendrites – some measuring twice as long as the cell
body – this difference is significant (e.g. overall, Langerhans cells
can cover a quarter of the total projected skin surface area, while
their bodies alone cover just ,5%) [23]. Therefore, if all the
projections penetrate the skin to the Langerhans cell layer, 6728
projections (i.e. using two Nanopatches; 3364 projections per
Nanopatch
TM covering 0.16 cm
2 of skin) will accordingly target
the bodies of 2000 Langerhans cells – or, when we also take into
account the dendrites, about 10000 Langerhans cells (of an
available 17350 resident under the Nanopatch
TM).
Penetrating deeper into the dermis will also target vaccine
directly to other classes of APCs [24], that have a less tightly-
defined location [25]. Using the knowledge of there being a third
of dermal APCs – compared to Langerhans cells in the epidermis –
their location, and shorter dendrites [25] we again applied our
probability analysis to estimate that our Nanopatch
TM designs
would target the bodies of approximately 500 dermal APCs, or
about 3700 APCs (of an available 7360 residing in the dermis)
when we also take into account contact with the cell dendrite arms.
In summary, our Nanopatch
TM design for this experiment was
theoretically configured to deliver antigen directly to more than
50% of both the epidermal and dermal APCs available under the
patch area within the skin – without relying on antigen diffusing
away from the projections.
Translating theoretical skin APC targeting into a practical
Nanopatch
TM design
Guided by our theoretical probability-based analysis, we
designed devices with arrays of densely-packed silicon projections
(each ,110 mm in length; with a cone height of 40 mm, at a
density of 21025/cm
2; distributed in 464 mm arrays): also
designed to be slender enough to puncture individual cells
without inducing significant cell death, but at the same time
mechanically strong enough to be pushed through the stratum
corneum without breaking. To achieve this balance, the
projection tips for this experiment were designed to be sharp,
tapering down to ,1000 nm at the tips, which, when applied to
skin at low speeds (,1 m/s), were predicted to induce minimal
cell death [17], [18]. We designed the spacing between the
projections to be sufficiently close for the Nanopatches to be
practically sized for skin application; while providing enough
space for the skin to deflect and compress around the projections
during penetration. We fabricated Nanopatches from silicon
wafers with Deep Reactive Ion Etching – a method typically used
in industry and potentially suitable to high volume manufacture
at low unit cost [26].
Nanopatch
TM projections consistently penetrate the skin
surface, through to the upper dermis
We then applied the Nanopatches to the skin, first with the goal
of establishing the desired consistent and repeatable projection
penetration through the epidermis and into the upper dermis.
First, using scanning electron microscopy images of the skin
surface following application, we observed 9362.9% (mean 6 SD;
n=350 projections) of the projections penetrated the skin. These
data show consistently, that most of projections breach the skin
barrier.
We then progressed to measure how far the projections
penetrate into the skin. Using the delivery of lipophilic dye by
the Nanopatch
TM (fluorescent DiD; imaged by confocal micros-
copy), Fig. 2m shows we measured the resultant distal tip
penetration depth of 42610 mm (mean 6 SD; n=350 projections,
5 ears) – extending through the epidermis (17.1 mm in thickness
[21]) and into the upper dermis by 25 mm. And in separate
experiments, we observed the in situ projection track pathways (i.e.
the ‘holes’ left behind in the skin by projections; not reliant on
dyes; obtained with cryo-scanning electron microscopy (SEM) in
which, C57BL/6 mouse ear skin was frozen when the patch was in
place). Fig. 2d shows a representative projection track pathway
piercing fully through the stratum corneum and epidermis – and
into the upper dermis. These qualitative observations are
consistent with the quantitative lipophilic dye measurements.
Influenza antigen is directly deposited to thousands of
epidermal and dermal APCs, in close accordance with
probability-based design
Having established the Nanopatch
TM projections achieve the
desired penetration into skin, we then measured the resultant
delivery of influenza vaccine directly to skin APCs – in practice.
Each Nanopatch
TM was coated with commercially-available
trivalent influenza vaccine (FluvaxH2008; CSL Ltd, Parkville,
Australia) and applied to the inner earlobe of anaesthetized female
6–8 week old C57BL/6 mice.
Using immunofluorescence microscopy (Fig 2e–h side view
and 2i–l top view); and, in three dimensions, (Video S1), we
found that 40619% of all the projections directly deposited
antigen in contact with epidermal and upper dermal MHC class
II positive cells. We also examined the skin area subjected to
Nanopatch
TM application and found the Nanopatches directly
targeted antigen to 9.265.2% of the cell bodies of resident MHC
class II cells imaged within the ‘targeting zone’ (i.e. the skin area
the Nanopatch
TM is applied to) of epidermis and upper dermis.
We measured the overall density of MHC class II cells at
7726212 cells/mm
2, which is nearly identical with the sum of
Skin Targeted Vaccinations
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[25].
We then considered the population of MHC class II cells are the
Langerhans cells – with a density of 542617 cells/mm
2 at the
suprabasal location within the mouse ear (same strain and site)
[22]. Thus, we derived from experiment that the bodies of
approximately 1600 Langerhans cells were directly targeted by
applying two of our prototype Nanopatches to each mouse. This
result agrees approximately with our original theoretical expecta-
tion of Nanopatches targeting 2000 Langerhans cell bodies; when
we also take into account measurements showing that about 93%
of the Nanopatch
TM projections penetrate the skin; then our
theoretical targeted Langerhans cell body population becomes
1870 cells – even closer to the observed result in practice. We have
shown that Nanopatches target vaccine to the desired skin APCs,
in populations agreeing well with our original probability-based
prediction used to guide the device design. When we also take into
account the dendrites extending from these cell bodies, the
number of APCs directly targeted by antigen is significantly
greater. For example, for Langerhans cells, this could be greater
than 9000 of the approximately 17000 resident Langerhans cells in
skin under contact of both Nanopatches (0.32 cm
2).
Looking then deeper into the skin at the dermal APCs – within
the same skin area under the Nanopatches – we determined by
experiment that about 680 cell bodies were targeted (with further
analysis of Fig 2i–l ) which is higher than the theoretical
calculation of 450 (taking into account 93% of the projections
penetrate the skin). When we theoretically also account for the
dendrites, then we could have targeted antigen directly to as many
as 5000 of the total of approximately 7360 dermal APCs.
Therefore, we have confirmed by experiment that antigen was
directly delivered to more than half of the APCs residing in both
the epidermal and dermis – also agreeing very well with our
probability-based analysis guiding our Nanopatch
TM design.
Nanopatch
TM vaccination of mice yields equivalent total
anti-influenza IgG responses as intramuscular injection,
but with more than 100-fold less antigen delivered to the
skin
Mice were vaccinated once by applying Nanopatches coated
with FluvaxH to both ears and a range of doses were tested across
different experimental groups. After application, each Nano-
patch
TM was kept in place on the skin for 2 minutes, to give
adequate time for the vaccine to dissolve and diffuse into the skin
subsurface (Supporting Document Supplementaty Figure
S1). Additional groups of mice were vaccinated by needle and
syringe in the caudal thigh muscle. Following this single
vaccination, all mice were bled at 3 weeks and also at 2 months.
Serum antibodies (IgG) to vaccine antigens were assessed by
ELISA [27] (Fig 3a). First, considering the 3 week bleed data
(Fig 3a, upper panel) in needle and syringe vaccinated mice,
reducing the dose by 10-fold gave a significantly lower response
(p=0.029, Mann-Whitney U test), and by a further 10-fold gave a
weak but measureable response in only 3 of 4 animals. In contrast,
antigen delivered to the skin using the Nanopatch
TM gave
antibody responses even at the lowest measured delivered dose
tested (6.5 ng), and with a dose of 34 ng showing no significant
difference from the 6000 ng intramuscular dose (p=0.11). This
indicates that equivalent high antibody responses can be obtained
with the Nanopatch
TM compared to intramuscular injection with
more than 100-fold less antigen delivered to the skin. These
responses persisted at high levels for at least 2 months (Fig 3a,
lower panel).
More than a 100-fold reduction of delivered antigen dose
was observed for functionally relevant antibody (HI)
responses, for three strains, when the vaccine was
administered using the Nanopatch
TM
We then examined the functional relevance of the antibody
produced in protection against the influenza virus. To do this, we
tested the same sera against each of the three vaccine component
strains of virus for hemagglutination-inhibitory (HI) activity
(Fig. 3b). The HI activity assay is the most widely accepted ‘gold
standard’ used as the surrogate for influenza protective effective-
ness [28], [29].
First, we consider the H1N1 component of the Fluvax 2008H.
We see, by three weeks after vaccination, that all the Nano-
patch
TM vaccinated groups – with delivered doses ranging from
538 ng down to 34 ng – generated equivalent or higher HI titers
than 6000 ng intramuscularly vaccinated group. At the lowest
Nanopatch
TM dose of just 6.5 ng, the HI titer was below responses
generated by a 6000 ng intramuscular injection, but still greater
than 600 ng intramuscularly vaccinated mice. Then, at two
months after vaccination, the comparison between the Nano-
patch
TM and intramuscular groups yielded the same outcome.
Second, turning to the H3N2 component of Fluvax 2008H,w e
observe that in all doses the Nanopatch
TM delivery (spanning from
538 ng right down to 6.5 ng) induced equivalent or higher HI
titers compared to 6000 ng intramuscular injection, at three weeks
following vaccination. Following this, at 2 months, we again see
significant HI activity maintained in the Nanopatch
TM vaccinated
mice compared to the intramuscular injected groups. With further
examination of the H3N2 component, we see that while none of
the intramuscular injections did achieve an HI titer of 1:40 (even
with the highest dose) – which is the minimum level sufficient to
correlate with protection in humans [30] ; the Nanopatch
TM-
delivered vaccine yielded HI titers generally above this critical
level.
Third, considering the type B virus component of the Fluvax
2008H, we see Nanopatch
TM delivery of low doses of HA induced
substantial HI activity above the critical value of 1:40 at 3 weeks,
again indicative of protection at doses as low as 34 ng compared to
6000 ng with intramuscular injection. Furthermore, the antibody
levels were maintained after 2 months above this critical level in all
doses that were 34 ng or higher.
Collectively for each of the three strains, more than a 100-fold
reduction of delivered antigen dose was observed for HI responses
when the vaccine was administered using the Nanopatch
TM –a
similar magnitude of improvement as was observed from the IgG
antibody responses in the ELISA.
Delivering an influenza vaccine by Nanopatch
TM induces
a protective immune response against viral challenge
Although the HI assay is a widely accepted correlate for
vaccination protection against influenza virus infection (discussed
in many publications, with [28], [29] as two examples), we decided
also to measure whether our Nanopatch
TM-delivered vaccine
induced a protective response against influenza virus challenge. To
carry out this part of the study, we could not use the commercial
trivalent vaccine (FluvaxH 2008) because mice cannot be infected
with these human strains of influenza. Therefore, as an alternative,
we used a split virion vaccine preparation, based on the mouse-
adapted A/Puerto Rico 8/34 strain [31] for use in the protection
assays (described in Methods). We see in Fig. 4 that delivering the
vaccine by Nanopatch
TM – even with delivered doses as low as
34 ng – induces a protective immune response, as mice exhibited
no substantial weight loss or clinical signs of diseases. In contrast
Skin Targeted Vaccinations
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the humane end-point after dramatic weight loss.
Discussion
In this study we demonstrated that the Nanopatches deliver
influenza vaccine to directly contact thousands of skin APCs
according to design, inducing functionally protective immune
responses in mice comparable to the vaccine delivered intramus-
cularly with the needle and syringe, but with less than 1/100
th of
the delivered dose. This result is an order of magnitude higher
than has been previously reported with other delivery devices with
only one vaccination, without using adjuvants (and thus,
mitigating risk of adjuvant induced adverse reactions) [6]. This
significant reduction in the amount of antigen needed to induce an
immune response is most likely the result of directly targeting
vaccine to a higher proportion of viable APCs in skin (e.g. achieved
targeting of several thousands of Langerhans cells and dermal
APCs per 0.32 cm
2 of targeted skin) than current delivery
methods.
Although it is considered important to target antigen to APCs, it
is not known how many cells should be targeted for effective or
optimized vaccination. This is the case for both mice and humans.
Therefore it follows that the thresholds for eliciting protective
immune responses in both mice and humans is also not known. In
this paper, we uniquely contribute to the body of knowledge by:
(a). Using a probabilistically guided approach to directly target
mice to more than 50% of both epidermal and dermal APCs
(beneath the patch area). (b). Demonstrating by experiment in
mice that antigen is directly deposited to thousands of epidermal
and dermal APCs (the bodies of 1600 LC, up to 9000 when we
consider the dendrites; to bodies of 680 dermal APC, up to 5000
Figure 3. Immune responses induced by influenza vaccine delivered by Nanopatch
TM and intramuscular injection. Nanopatches were
coated with incremental and controlled doses of the vaccine FluvaxH2008 by the addition of different doses of FluvaxH in the same volume of
methylcellulose. The doses indicated are the total hemagglutinin amounts of the three viral strains included in the vaccine. Seven microliter of the
coating solution, containing FluvaxH and methylcellulose was applied on each Nanopatch
TM followed by drying with a stream of nitrogen gas.
Delivered doses were determined by Coomassie Blue R-250 dye recovery. C57BL/6 mice were vaccinated once with one Nanopatch
TM on each inner
ear lobe or by intramuscular injection with the indicated doses and were bled at 3 weeks and again at 2 months. (a,) Individual serum samples (3
weeks, blue circles; 2 months, Green squares) were assayed by ELISA on FluvaxH-coated wells and IgG titers for each individual animal are shown as a
closed circle with the geometric mean titer (GMT) as a line. (b,) Sera (3 weeks, blue bars; 2 months, green bars) were assayed for hemagglutinin
inhibition (HI) activity
38 against each of the three component viruses included in the trivalent vaccine as indicated above the panels. Bars are the GMT
and error bars are the standard error of the mean.
doi:10.1371/journal.pone.0010266.g003
Figure 4. Influenza challenge protection study using PR8 strain. Groups of five C57BL/6 mice were vaccinated with either PBS or different
doses of a preparation of split virus vaccine comprising mouse-adapted influenza virus A/Puerto Rico 8/34. Mice were given the vaccine at the doses
of 34 ng and 105 ng HA in the form of two Nanopatches to the ears, or with a dose of 6000 ng HA by IM injection with needle and syringe. Thirty six
days after the vaccination, mice were challenged with 200 plaque forming units of virus (corresponding to approx. 4 times the lethal dose). The body
weights of mice were recorded daily after the challenge. Mice were euthanized at a previously determined humane endpoint indicative of severe
illness that would otherwise progress to death.
doi:10.1371/journal.pone.0010266.g004
Skin Targeted Vaccinations
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with probability-based design. (c). Showing that vaccination of
mice yields equivalent total anti-influenza IgG responses as
intramuscular injection, but with more than 100-fold less antigen
delivered to the skin.
Since a protective response has been elicited in this study,
obviously the cells targeted have been above the threshold. Our
work in this paper paves the way to finding this threshold in future
work. We have now established a rational design and engineering
approach for designing Nanopatches to target discrete and
incremental ranges of APC populations (both epidermal and
dermal). This will be applied in follow-up studies on mice and on
humans.
Furthermore, we have shown the actual number and location of
targeted APCs– forboth theepidermisanddermis –agreeswith the
probability-based prediction used to guide the device design. This is
important, because it demonstrates that a mathematical/engineer-
ing design approach ‘from the ground up’ does indeed achieve the
desired APCtargeting–therebyputtinginplacearigoroustemplate
for further extending this uniquely precise delivery approach to
targeting vaccines to selectively different quantities of APCs.
However, these studies have only been performed with one
Nanopatch
TM configuration and we believe there is much scope
to apply this device, together with it’s underlying probability-based
design approach, as a toolbox for further studies optimizing many
vaccines – including those for influenza.
We foresee, most importantly, that our study positions the
Nanopatch
TM for extension beyond mice and into humans. In doing
this, we will again apply the same idea of tailoring the Nanopatch
TM
deviceto directlytargetvaccine to large populationsofthe epidermal
and dermal cells within human skin – accounting for the
physiological differences between the skin of the two species. We
expect the spatial targeting considerations to be similar, because the
density of the characterized APCs resident in the skin is comparable
(e.g. Langerhans cell density is 542617 mm
22 inmouse ear skin(for
the strain tested in this study) [22]; and 730660 mm
22 in human
upper arm skin [32]). However, the human skin is thicker than
mouse skin (e.g., mouse ear epidermis is 17.562.1 mm [21]; while a
candidate vaccination site for humans is the forearm, with a dorsal
epidermis is 61.3611.0 mm [33]). And correspondingly, the depth of
Langerhans cell locations (for example), in the supra-basal region, is
greater in humans. Reaching this human target, together with
underlying dermal APCs, will require deeper penetration of the
projections, which could be achieved by slightly longer projections,
and exploiting the skin’s viscoelastic behavior (e.g. by altering the
strain-rate of Nanopatch
TM application).
It is worth noting that we have also engineered Nanopatches as
practical delivery devices for potential use in humans. They are
produced by a simple manufacturing process with the potential for
high volume production. By dry-coating vaccine to the Nano-
patch
TM tips, we expect to minimize or eliminate the need to
refrigerate vaccines, as is currently required for most vaccines. The
basis for this expectation is that reformulating liquid vaccines into
dry-form micro-particles makes them thermostable [34], and we are
applying very similar coating principles with our Nanopatch
TM.
Thermostable vaccines have the potential to remove the need for
refrigeration – which particularly burden infrastructure in the
developing world and/or a pandemic requiring very rapid
transportation. The potential for self-application is an added
advantage. Nanopatches are also anticipated to avoid needle-
phobia, needle-stick injuries (causing more than 500,000 deaths per
year), and cross-contamination (e.g. 21 million cases of hepatitis B
transmission annually) associated with the hypodermic syringe [35],
[36]. With these collective attributes, Nanopatches should be
suitable for general immunization programs for many vaccines,
particularly where there is a need to avoid the use of needle and
syringe as in vaccinations of infants and children. Nanopatches are
safe to use in humans because it is made out of silicon and coated
with gold and the microprojections do not break during insertion
[37,38]. In a very unlikely case of breakage (expected to be %0.1%
of projections, the effects on safety are expected to be minimal
because both gold and silicon have been approved as safe by the
FDA for skin use [39]. Furthermore gold particles have been used
extensively in gene gun DNA immunisations approximately 1mg
dose delivered into theskinwithout anydeleteriouseffects(eg.Phase
1 safety and immune response studies of a DNA vaccine encoding
hepatitis B surface antigen delivered by a gene delivery device [40].
Any microprojections remaining in the skin will eventually be
sloughed off with the skin.
The cost of a vaccination depends on many factors, including:
the delivery device (e.g. needle and syringe, or alternative), the
vaccine, the cost of transportation, cold chain and the use of a
qualified medical practitioner to administer the vaccine and the
disposal cost of the device (and packaging). For example, cold
chain can contribute 80% of the cost of vaccination programs in
developing countries [41]. Although the cost of the Nanopatch is
comparable to the cost of the needle and syringe, we believe the
ultimate overall cost of vaccine administration via Nanopatch will
be considerably cheaper than the needle and syringe, because the
Nanopatch is expected to outcompete the needle and syringe in
each of the attributes listed.
We speculate that in the future we could rollout a rapid
response to pandemic influenza to a much greater population via
highly-immunogenic Nanopatch
TM-delivered vaccine sent in the
mail to individuals for self-administration.
Materials and Methods
Ethics Statement
All animal experiments were conducted according to the
University of Queensland animal ethics regulations.
Vaccine used
We used was the seasonal human influenza vaccine, Flu-
vax2008H, manufactured by CSL Ltd, Parkville Australia which
contains 15 mg hemagglutinin (HA) per 0.5ml of each of the three
viral strains bearing the surface antigens of A/Brisbane/10/2007
(H3N2), A/Solomon Islands/3/2006 (H1N1) and B/Florida/4/
2006.
Coating of Nanopatches
Each Nanopatch
TM (0.16 cm
2) was coated with commercially-
available trivalent influenza vaccine (Fluvax2008H CSL Ltd,
Parkville Australia) using a nitrogen-jet drying coating method
[37]. Briefly, 7 ml of coating solution, containing methylcellulose
and the vaccine, was applied to each Nanopatch
TM. A nitrogen
gas jet (6–8 m/s) evenly distributed the solution on the whole
Nanopatch
TM, while simultaneously localizing the vaccine on the
projections where it would be delivered to skin.
Measurement of projection penetration in skin, using
fluorescent dye
Four DiD (1,19-dioctadecyl-3,3,39,39-tetramethylindocarbocya-
nine per-chlorate) coated patches were applied to the inner earlobe
of anaesthetized female 6–8 week old C57BL/6 mice (one patch
per ear) with a custom spring based applicator device at 1.96 m/s.
After application, each Nanopatch
TM was kept in place on the skin
for 2 minutes. Penetration and release profiles were obtained by
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microscopy (MPM, Zeiss 510 Meta, Germany). To track the
delivery of fluorescent chemicals from coated microprojections in
the skin, we used MPM to produce a series of images at successive
skin depths, and then repeated the procedure at later time points.
The projection penetration depth for each projection set was
determined by image analysis. The delivery of DiD from 130
projections was measured for each ear with a total of 4 ears
analysed (i.e. n=4). The morphology of projections was examined
before and after application to the skin with Scanning Electron
Microscopy (SEM, JEOL 6400) to qualitatively confirm the
coating and release.
Observation of projection penetration in skin, using
Cyro-SEM
Cryo-SEM was employed to visualise the penetration of
projections in skin. A patch was applied to the skin by a custom
spring based applicator device at 1.96 m/s. With the projections in
place, the skin and patch assembly was frozen in liquid nitrogen
for 10 seconds. To avoid condensation accumulation on the skin,
the array was removed in a cryo-preparation chamber, under
vacuum. Then the skin was cut into pieces in the vacuum chamber
and the intersection of the skin was observed under SEM (Phillips
XL30) at room temperature. Three patches were also applied onto
three mouse ears at a consistent and repeatable velocity, by a
custom spring-based applicator device at 1.96 m/s. The number
of projections which pierced stratum corneum was counted.
Histology and immunostaining
Four Cy3 labeled FluvaxH coated patches were applied to the
inner earlobe of anaesthetized female 6–8 week old C57BL/6
mice (one patch per ear) with a custom spring based applicator
device at 1.96 m/s. After application, each Nanopatch was kept in
place on the skin for 2 minutes. Mice were subsequently sacrificed
and ears excised and the skin was fixed in 2% paraformaldehyde
in 0.1 M phosphate buffer at room temperature for 10 minutes.
The tissue was then cryopreserved and then sectioned to 10 mm
wide and counterstained with Hoechst 33342. A stock solution of
10 mg/ml Hoechst 33342 in DMSO was prepared. A working
solution was made by a 1:10,000 dilution in TBS for nuclei
staining. Tissue sections were treated with the working solution of
Hoechst 33342 solution and incubated for 10–20 minutes at room
temperature. Finally, the tissue sections were rinsed for 3615 min-
utes in TBS. The tissue sections were immunostained with mouse
anti-MHC II-FITC (eBioscience, San Diego, CA USA) at 1:500
for 1 hour at room temperature. The sections were then rinsed for
3615 minutes in TBS. The tissue was then mounted with Prolong
Anti-fade Gold (Invitrogen, Carlsbad, CA USA).
Whole ears were split at the dermis-cartilage junction where the
epidermis and dermis from the application side were retained for
staining. The split-ear tissue was fixed in 2% paraformaldehyde in
0.1M phosphate buffer at room temperature for 30 minutes. The
tissue was then washed 3615 minutes in TBS prior to permeabi-
lization with 0.1% Triton-X 100 in 0.1M phosphate buffer at room
temperature for 15 minutes. The tissue was then washed again
3615 minutesinTBS.Thetissueswereimmunostained with mouse
anti-MHC II-FITC (eBioscience, San Diego, CA USA) at 1:200 for
1 hour at room temperature. The sections were then rinsed for
3615 minutes in TBS. The tissue was then mounted with Prolong
Anti-fade Gold (Invitrogen, Carlsbad, CA USA).
We have defined the targeting of antigen directly to an APC as:
(a) the antigen co-localized with the APC (i.e. the color yellow),
and/or
(b) the antigen in direct contact with the APC. We define this
contact as there not being any ‘empty’ voxels between the
fluorescent signals from the antigen and the APC. The voxel
size is 0.82 mm 60.82 mm 61.8 mm (x, y, z), defining the
resolution of this direct contact event.
Use of Coomassie Blue R-250 as the tracer dye to
determine the vaccine dose delivered
We measured the dose of FluvaxH antigen delivered to the skin
using Coomassie Blue R 250 dye as a tracer. Correspondingly, the
mass of delivered FluvaxH antigen was determined by the ratio of
FluvaxH to Coomassie Blue R-250 contained in the coating
solution. Five Nanopatches were coated with Fluvax 2008H,
Coomassie Blue R-250 dye and methylcellulose. With the same
applicators, the coated Nanopatches were applied to mouse ears
(n=5). Then the skin sites were gently and thoroughly cleaned
with a cotton swab moistened with physiological saline immedi-
ately following patch removal. Subsequently, the skin from the
patched area was cut and then homogenized in 1 ml of 70%
ethanol at 55uC for 2 hours under stirring to extract the
Coomassie Blue in the skin. Finally the absorbance (at
lmax=592 nm) of the eluate for the 5 samples was measured
and the percentage of Coomassie Blue delivered to the skin from
each Nanopatch
TM was calculated to be 6.46%60.84% (Mean6
SEM) of Coomassie Blue applied to each mouse ear. Using
scanning electron microscopy images of coated Nanopatches, we
then examined the coating morphology, and found the coating
thickness was uniform across a given Nanopatch
TM and repeatable
between Nanopatches. This, for example, is demonstrated by the
uniform coating thickness at the middle of the cylindrical part of
projections (2.1060.18 mm; n=5). Furthermore, uniformity of
coating to projections was independently confirmed by consistent
fluorescence intensity on the projections – measured by confocal
microscopy images of Nanopatches coated with a fluorescent dye
(rhodamine-dextran; used as a surrogate of vaccine for coating).
This collective work validated the assumption that a consistent and
repeatable portion of FluvaxH antigen was delivered to skin by
each coated Nanopatch
TM.
Vaccination of mice
C57BL/6 female mice (groups of five) were vaccinated once by
applying Nanopatches dry coated with Fluvax 2008H to the inner
lobe of each ear (two Nanopatches per mouse) and held in place for
2 min for the vaccine to diffuse into the epidermis/dermis. A range
of doses weretested across different experimental groups. Additional
groups of mice were vaccinated by needle and syringe in the caudal
thigh muscle. The doses shown are the total HA amounts of the
three viral strains combined delivered under the skin of the three
different strains present in Fluvax 2008H. Following the single
vaccination, all mice were bled at 3 weeks and also at 2 months. The
sera were separated and stored frozen at 220uC till assays were
performed. All animal experiments wereconducted according to the
University of Queensland animal ethics regulations.
Serological analyses
ELISA was performed as previously described [42]. Briefly, the
ELISA plates (Nunc Maxisorp) were coated with the commercial
trivalent split virion Fluvax2008H. The vaccine was diluted at a
concentration equivalent to 3 mg/ml total HA in 0.1M sodium
bicarbonate buffer and 50ml of this solution was added to each well
of the ELISA plates and incubated overnight at 4uC. The plates
were blocked with 4mg/ml BSA and used to determine the titers
of antigen specific IgG induced. The color development was
Skin Targeted Vaccinations
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sulfonic acid]) (Sigma cat. no. A-1888) as the substrate. The
absorbance readings at 405 nm were measured against control
wells containing no antiserum in the reaction. Each sample was
individually analyzed.
Hemagglutination-Inhibition Assay
Sera were treated with receptor destroying enzyme (RDE II,
Denka Seiken Co. Ltd.) prior to HI analysis to remove nonspecific
inhibitors of agglutination. Samples were diluted 1in 5 in RDE
and held at 37uC overnight. An equal volume of sodium citrate
1.6% (w/v) was then added and held at 56uC for 2 hr to neutralize
RDE activity. The HI test was performed against each of the three
purified influenza viruses present in the FluvaxH2008 formulation
using chicken red blood cells by established methods [43] adapted
to microtiter format.
Viral challenge
Mice (n=5) were vaccinated with a preparation of mouse
adapted influenza virus A/Puerto Rico/8/34 split virion [31].
Mice received 34 ng or 105 ng by Nanopatch
TM or 6000 ng by
intramuscular injection. Unimmunized mice were used as a
control. Thirty six days after the vaccination, mice were
challenged with a lethal dose of 200 plaque forming units of the
virus. Body weights and clinical signs of mice were recorded daily
after challenge and, where necessary, mice were culled at a
predetermined humane endpoint under guidelines approved by
the University of Melbourne Animal Ethics Committee.
Statistical analyses
ELISA, HI titers and the data in the Fig 2 were analyzed by
Mann-Whitney U test using GraphPad Prism 5 software (La Jolla,
CA, USA).
Supporting Information
Figure S1 Figure S1 shows the normalized release of influenza
vaccine into skin, following application of Nanopatches bearing
dry-coated influenza vaccine to the inner lobe of the mouse ear for
different times. The data shows that the released amount of
influenza vaccine in the skin does not show statistical difference
(p=0.46) for Nanopatch application time of 2 and 5 minutes. For
each application time (0.5, 2 and 5 minutes), a group of 6 coated
patches were applied on 6 individual mouse ears for measurement
of the released amount of coating in the skin. Video S1. This video
shows part of a Nanopatch site in 3D. The Fluvax 2008H payload
is red (Fluvax-Cy3) and the antigen presenting cells are shown in
green (MHC class II). The image only contains the epidermis and
the nuclei are shown in blue (Hoechst 33342). The skin was fixed
in paraformaldehyde immediately after the patch was applied.
Immunostaining for MHC class II immediately followed fixation.
The Z stack video was generated by 3D rendering a z-stack in
Imaris. The initial scene is the full image of Figure 2 (i)–(l). The
movie then zooms in on a deposit site where the Fluvax co-
localizes with an antigen presenting cell.
Found at: doi:10.1371/journal.pone.0010266.s001 (0.25 MB TIF)
Video S1 Multimedia File Video S1
Found at: doi:10.1371/journal.pone.0010266.s002 (6.02 MB AVI)
Acknowledgments
Nanopatches were fabricated at the Rutherford Appleton Laboratories,
UK, by Derek Jenkins. Marion Brunck and Sally Yukiko are acknowledged
for the technical assistance and Kerry Fagan, Chelsea Stewart, Trish
Hitchcock and others at the Animal Facility in the AIBN at The University
of Queensland for the animal care. We wish to thank Dr. Christopher
Flaim for his suggestions.
Author Contributions
Conceived and designed the experiments: GJF XC TWP MSR IHF LEB
MAK. Performed the experiments: GJF XC TWP MLC EJF. Analyzed the
data: GJF XC TWP MLC EJF IHF LEB MAK. Contributed reagents/
materials/analysis tools: GJF XC TWP MLC EJF MSR IHF LEB MAK.
Wrote the paper: GJF XC TWP MLC MSR LEB MAK.
References
1. Seielstad M (2000) Whiffs of selection. Nat Genet 26: 131–132.
2. Kupper TS, Fuhlbrigge RC (2004) Immune surveillance in the skin:
Mechanisms and clinical consequences. Nat Rev Immunol 4: 211–222.
3. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM (2004) Dose sparing
with intradermal injection of influenza vaccine. New Engl J Med 351:
2295–2301.
4. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O,
et al. (2009) Safety and efficacy of a novel microneedle device for dose sparing
intradermal influenza vaccination in healthy adults. Vaccine 27: 454–459.
5. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of
swine-origin H1N1 influenza virus. Nature 459: 931–939.
6. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: Current state and future
trends. Immunol. Cell Biol 82: 488–496.
7. Palache B (2008) New vaccine approaches for seasonal and pandemic influenza.
Vaccine 26: 6232–6236.
8. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, et al. (2007)
Evaluation of the clinical performance of a new intradermal vaccine admini-
stration technique and associated delivery system. Vaccine 25: 8833–
8842.
9. Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, et al. (2009) Immunization by
vaccine-coated microneedle arrays protects against lethal influenza virus
challenge. Proc Natl Acad Sci USA 106: 7968–7973.
10. Koutsonanos DG, Martin MDP, Zarnitsyn VG, Sullivan SP, Compans RW, et
al. (2009) Transdermal influenza immunization with vaccine-coated microneedle
arrays. Plos One 4: e4773.
11. Matriano JA, Cormier M, Johnson J, Young WA, Buttery M, et al. (2002)
Macroflux (R) microprojection array patch technology: A new and efficient
approach for intracutaneous immunization. Pharm Res 19: 63–70.
12. Widera G, Johnson J, Kim L, Libiran L, Nyam K, et al. (2006) Effect of delivery
parameters on immunization to ovalbumin following intracutaneous adminis-
tration by a coated microneedle array patch system. Vaccine 24: 1653–1664.
13. Glenn GM, Kenney RT, Hammond SA, Ellingsworth LR (2003) Transcuta-
neous immunization and immunostimulant strategies. Expert RevVaccines 2:
253–267.
14. Furth PA, Shamay A, Hennighausen L (1995) Gene transfer into mammalian
cells by jet injection. Hybridoma 14: 149–152.
15. Kendall M, Mitchell T, Wrighton-Smith P (2004) Intradermal ballistic delivery
of micro-particles into excised human skin for pharmaceutical applications.
J Biomech 37: 1733–1741.
16. Merad M, Ginhoux F, Collin M (2008) Origin, homeostasis and function of
Langerhans cells and other langerin-expressing dendritic cells. Nat Rev
Immunol 8: 935–947.
17. Doukas AG, Flotte TJ (1996) Physical characteristics and biological effects of
laser-induced stress waves. Ultrasound Med Biol 22: 151–164 (1996).
18. Han SW, Nakamura C, Obataya I, Nakamura N, Miyake J (2005) Gene
expression using an ultrathin needle enabling accurate displacement and low
invasiveness. Biochem Bioph Res Co 332: 633–639.
19. Palese P (2004) Influenza: old and new threats. Nat Med 10: S82–S87.
20. Poland GA (2006) Vaccines against avian influenza - A race against time. New
Engl J Med 354: 1411–1413.
21. Mulholland WJ, Arbuthnott EAH, Bellhouse BJ, Cornhill JF, Austyn JM, et al.
(2006) Multiphoton high-resolution 3D imaging of Langerhans cells and
keratinocytes in the mouse skin model adopted for epidermal powdered
immunization. J Invest Dermatol 126: 1541–1548.
22. Koyama Y, Nagao S, Ohashi K, Takahashi H, Marunouchi T (1987) Sex-
differences in the densities of epidermal Langerhans cells of the mouse. J Invest
Dermatol 88: 541–544.
23. Yu RC, Abrams DC, Alaibac M, Chu AC (1994) Morphological and
quantitative-analyses of normal epidermal Langerhans cells using confocal
scanning laser microscopy. Brit J Dermatol 131: 843–848.
24. Lopez-Bravo M, Ardavin C (2008) In vivo induction of immune responses to
pathogens by conventional dendritic cells. Immunity 29: 343–351.
Skin Targeted Vaccinations
PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e1026625. Ng LG, Hsu A, Mandell MA, Roediger B, Hoeller C, et al. (2008) Migratory
Dermal Dendritic Cells Act as Rapid Sensors of Protozoan Parasites. Plos
Pathog 4: e1000222.
26. Reed ML, Lye WK (2004) Microsystems for Drug and Gene Delivery. Proc
IEEE 92: 56–75.
27. Fernando GJP, Stewart TJ, Tindle RW, Frazer IH (1998) Th2-type CD4(+) cells
neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
J Immunol 161: 2421–2427.
28. Noah DL, Hill H, Hines D, White EL, Wolff MC (2009) Qualification of the
Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine
Licensure. Clin Vaccine Immunol 16: 558–566.
29. Hobson D, Curry RL, Beare AS, Wardgard A (1972) A Role of serum
hemagglutination-in hibiting antibody in protection against challenge infection
with influenza A2 and B viruses. J Hygiene 70: 767–777.
30. Food & Drug Administration (2007) Guidance for industry: clinical data needed
to support for licensure of seasonal inactivated influenza vaccines. http://www.
fda.gov/cber/gdlns/trifluvac.htm#iii).
31. Coulter A, Wong TY, Drane D, Bates J, Macfarlan R, Cox J (1998) Studies on
experimental adjuvanted influenza vaccines: comparison of immune stimulating
complexes (Iscoms (TM)) and oil-in-water vaccines. Vaccine 16: 1243–1253.
32. Friedmann PS (1981) Disapperance of epidermal Langerhans cells during puva
therapy. Brit J Dermatol 105: 219–221.
33. Falstiejensen N, Spaun E, Brochnermortensen J, Falstiejensen S (1988) The
influence of epidermal thickness on thans-cutaneous oxygen-pressure measure-
ment in normal persons. Scand J Clin Lab Inv 48: 519–523.
34. Frolov VG, Seid RC, Odutayo O, Al-Khalili M, Yu JM, et al. (2008)
Transcutaneous delivery and thermostability of a dry trivalent inactivated
influenza vaccine patch. Influenza Other Respi. Viruses 2: 53–60.
35. Mitragotri S (2005) Immunization without needles. Nat Rev Immunol 5:
905–916.
36. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M (1999) Unsafe injections in
the developing world and transmission of bloodborne pathogens: a review. Bull
World Health Organ 77: 789–800.
37. Chen X, Prow TW, Crichton ML, Jenkins DWK, Roberts MS, et al. (2009) Dry-
coated microprojection array patches for targeted delivery of immunotherapeu-
tics to the skin. J Control Rel 139: 212–220.
38. Crichton ML, Ansaldo A, Chen X, Prow TW, Fernando GJP, et al. (2010) The
effect of strain rate on the precision of penetration of short densely-packed
microprojection array patches coated with vaccine. Biomaterials;Doi: 10.1016/
j.biomaterials.2010.02.022.
39. U.S. Food and Drug Administration. Available: http://www.accessdata.fda.gov/
scripts/cder/iig/getiigWEB.cfm.
40. Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, et al. (1999) Phase 1
safety and immune response studies of a DNA vaccine encoding hepatitis B
surface antigen delivered by a gene delivery device. Vaccine 17: 2826–2829.
41. Kols A, Sherris J, HPV vaccines: promise and challenges. Available: http://
www.path.org/files/jsrp13710.pdf.
42. Fernando GJP, Stenzel DJ, Tindle RW, Merza MS, Morein B, et al. (1995)
Peptide polymerization facilitates incorporation iscoms and increases antigen-
specific IgG2a production. Vaccine 13: 1460–1467.
43. Fazekas de St Groth S, Webster RG (1966) Disquisitions on original antigenic
sin. 1. Evidence in man. J Exp Med 124: 331.
Skin Targeted Vaccinations
PLoS ONE | www.plosone.org 11 April 2010 | Volume 5 | Issue 4 | e10266